CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$2.34 USD
-0.08 (-3.31%)
Updated Apr 29, 2024 04:00 PM ET
3-Hold of 5 3
C Value D Growth NA Momentum NA VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CASI 2.34 -0.08(-3.31%)
Will CASI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Other News for CASI
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
Casi Pharmaceuticals discloses development relating to dispute with Juventas
CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
Recap: CASI Pharmaceuticals Q4 Earnings
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS